NASDAQ:AKBA - Akebia Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.34 +0.31 (+2.81 %)
(As of 06/21/2018 08:13 AM ET)
Previous Close$11.03
Today's Range$10.98 - $11.60
52-Week Range$8.93 - $20.25
Volume466,538 shs
Average Volume395,424 shs
Market Capitalization$627.42 million
P/E Ratio-6.41
Dividend YieldN/A
Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat which is an oral therapy in a phase three development that has the potential to set a new standard of care in treatment of anemia associated with chronic kidney disease. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio2.89
Quick Ratio2.89


Trailing P/E Ratio-6.41
Forward P/E Ratio-5.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.98 million
Price / Sales3.62
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book4.50


EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-27.48%
Return on Equity-47.15%
Return on Assets-15.05%


Outstanding Shares56,880,000

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc. (NASDAQ:AKBA) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.01. The biopharmaceutical company had revenue of $45.93 million for the quarter, compared to the consensus estimate of $47.80 million. Akebia Therapeutics had a negative return on equity of 47.15% and a negative net margin of 27.48%. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

6 Wall Street analysts have issued 1 year price objectives for Akebia Therapeutics' stock. Their forecasts range from $17.00 to $30.00. On average, they anticipate Akebia Therapeutics' share price to reach $23.80 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (6/19/2018)
  • 2. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • John P. Butler, President, CEO & Director
  • Gavin T. Malenfant, Vice President-Operations
  • Jason A. Amello, CFO, Treasure, SVP & Principal Accounting Officer
  • Rita Jain, Chief Medical Officer & Senior Vice President
  • Michel Dahan, Chief Business Officer & Senior Vice President

Has Akebia Therapeutics been receiving favorable news coverage?

Media stories about AKBA stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a daily sentiment score of 0.03 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.17 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), Eagle Asset Management Inc. (4.79%), Millennium Management LLC (1.16%), DAFNA Capital Management LLC (1.07%), Northern Trust Corp (0.91%) and American Century Companies Inc. (0.88%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Wells Fargo & Company MN and Citigroup Inc.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was acquired by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Artal Group S.A., BlackRock Inc., CVI Holdings LLC, Stanley Laman Group Ltd., PNC Financial Services Group Inc., Point72 Asset Management L.P. and Spark Investment Management LLC. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $11.34.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $627.42 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

MarketBeat Community Rating for Akebia Therapeutics (AKBA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.